Cargando…
Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has particularly impacted patients with hemato-oncological malignancies, as they showed not only a higher propensity for severe courses but also weaker immune responses after vaccination. Still, data on the influen...
Autores principales: | Mair, M.J., Mitterer, M., Buratti, T., Berchtold, L., Fong, D., Preusser, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126224/ https://www.ncbi.nlm.nih.gov/pubmed/37196399 http://dx.doi.org/10.1016/j.esmoop.2023.101559 |
Ejemplares similares
-
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study
por: Mair, Maximilian J., et al.
Publicado: (2022) -
PRES in the course of hemato-oncological treatment in children
por: Musioł, Katarzyna, et al.
Publicado: (2017) -
Stem Cells in Hemato-Oncology
por: Damodar, S
Publicado: (2006) -
High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine
por: Fong, Dominic, et al.
Publicado: (2021) -
Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients
por: Caldwell, Louise, et al.
Publicado: (2022)